
Merck Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis
Merck, a leading science and technology company, today announced that its two Phase III EVOLUTION clinical trials (evolutionRMS 1 and evolutionRMS 2) investigating the efficacy and safety of evobrutinib did…











